These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38303354)

  • 1. [Two Cases of the Significant Liver Damage by Regorafenib].
    Machida T; Yoshida M; Saiga H; Koide T; Matsumoto A; Wada T; Tanaka H; Harada N; Mitsutsuji M; Samizo M
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1600-1602. PubMed ID: 38303354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
    Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer.
    Ogata K; Takamori H; Umezaki N; Yagi T; Ogawa K; Ozaki N; Hayashi H; Tanaka H; Ikuta Y; Doi K
    J Chemother; 2017 Oct; 29(5):314-316. PubMed ID: 27438692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral sensorineural hearing loss induced by regorafenib.
    Cheng J; Wang L; Zhu LN; Wang L
    J Clin Pharm Ther; 2019 Dec; 44(6):963-965. PubMed ID: 31381817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A Case of Recurrent Colorectal Cancer with Bilateral Ovarian Metastases That Were Reduced with Regorafenib Therapy].
    Nakae S; Nogi Y; Arima J; Okamoto D; Urakawa N; Fujikawa M; Gon H; Takebe A; Shinzeki M; Tanaka K; Senzaki H
    Gan To Kagaku Ryoho; 2017 Jul; 44(7):607-610. PubMed ID: 28790267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
    Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
    J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report.
    Akamine T; Ando K; Oki E; Saeki H; Nakashima Y; Imamura YU; Ohgaki K; Maehara Y
    Anticancer Res; 2015 Jul; 35(7):4037-41. PubMed ID: 26124352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer.
    Raissouni S; Quraishi Z; Al-Ghamdi M; Monzon J; Tang P; Vickers MM
    BMC Res Notes; 2015 Oct; 8():538. PubMed ID: 26438070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Stevens-Johnson syndrome induced by regorafenib in a patient with progressive recurrent rectal carcinoma].
    Mihara Y; Yamaguchi K; Nakama T; Nakayama G; Kamei H; Ishibashi N; Uchida S; Akagi Y; Ogata Y
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):233-6. PubMed ID: 25743146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study).
    Ishiyama S; Yamada T; Nakamura M; Enomoto M; Sugimoto K; Yokomizo H; Kosugi C; Ohta R; Ishimaru K; Sonoda H; Ishibashi K; Kuramochi H; Yoshida Y; Ichikawa D; Hirata K; Yoshida H; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
    Int J Clin Oncol; 2022 Aug; 27(8):1300-1308. PubMed ID: 35635652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
    Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW;
    Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib induced severe toxic hepatitis: characterization and discussion.
    Sacré A; Lanthier N; Dano H; Aydin S; Leggenhager D; Weber A; Dekairelle AF; De Cuyper A; Gala JL; Humblet Y; Sempoux C; Van den Eynde M
    Liver Int; 2016 Nov; 36(11):1590-1594. PubMed ID: 27500989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.
    Abou-Elkacem L; Arns S; Brix G; Gremse F; Zopf D; Kiessling F; Lederle W
    Mol Cancer Ther; 2013 Jul; 12(7):1322-31. PubMed ID: 23619301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report.
    Tsuchihashi K; Shimokawa H; Takayoshi K; Nio K; Aikawa T; Matsushita Y; Wada I; Arita S; Ariyama H; Kusaba H; Sonoda KH; Akashi K; Baba E
    Medicine (Baltimore); 2017 Oct; 96(42):e8285. PubMed ID: 29049226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    Trédan O; Provansal M; Abdeddaim C; Lardy-Cleaud A; Hardy-Bessard AC; Kalbacher E; Floquet A; Venat-Bouvet L; Lortholary A; Pop O; Frenel JS; Cancel M; Largillier R; Louvet C; You B; Zannetti A; Anota A; Treilleux I; Pissaloux D; Houlier A; Savoye AM; Mouret-Reynier MA; Meunier J; Levaché CB; Brocard F; Ray-Coquard I
    Gynecol Oncol; 2022 Jan; 164(1):18-26. PubMed ID: 34696892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
    Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
    Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer.
    Alandağ C; Karaman E; Yüce E
    Anticancer Drugs; 2022 Apr; 33(4):389-393. PubMed ID: 35266888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms.
    Maeda A; Irie K; Ando H; Hasegawa A; Taniguchi H; Kadowaki S; Muro K; Tajika M; Aoki M; Inaguma K; Kajita M; Fujimura A; Fukushima S
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):107-113. PubMed ID: 30368586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures.
    Yin Q; Guo N; Zhou X; Xu H; Lei S; Fu P; Zhong H
    BMC Nephrol; 2022 Mar; 23(1):112. PubMed ID: 35305559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.